Alzheimer's disease (AD) is a major public health issue facing the world's aging population;however, to date, there is no rapid and cost effective means for early diagnosis that is widely accessible. It has been suggested that a blood-based screening will become the first-step in the AD diagnostic process, although no such test currently exists. In our prior work through the Texas Alzheimer's Research &Care Consortium (TARCC), we created a serum-based screening algorithm that correctly classified 94% of those with and without AD. We then followed that work-up by creating a blood-based algorithm in the TARCC that worked across both serum and plasma that, when applied to the ADNI plasma samples, correctly classified 89% of those with and without AD in the entirely independent cohort. The long-term goal of this project is the validation of the our blood-based screening instrument for AD.
The specific aims of the current project are as follows:
Specific Aim 1 : To test the reliability and validity of our previously created blood-based screening algorithm, and Specific Aim 2: To validate our blood-based algorithms against other diagnostic modalities (i.e., neuropathological findings and CSF analyses). Multiplex serum- and plasma-based biomarker assays (using electrochemiluminescence) will be conducted on 1,100 samples from the TARCC and Mayo Clinic Jacksonville biobanks. The establishment of a blood-based screening instrument for AD will significantly change the field of geriatric medicine. Such a tool would fit into the existing medical infrastructure as a frontline population-based screening device where positive findings can be followed-up with clinical, imaging or CSF assessments. This overall approach will increase accessibility to standard care far beyond what can be offered by other methodologies. This approach will also provide a more rapid and cost-efficient means for screening into AD clinical trials.

Public Health Relevance

Alzheimer's disease (AD) is a major public health issue facing the world's aging population;however, to date, there is no rapid and cost effective means for screening all those at risk for having the disease. The relevance of the current proposal is the establishment of a blood-based screener for AD that can be used and implemented as a frontline assessment device for clinical and research purposes. The establishment of a blood-based screener for AD would change the field of geriatric medicine and increase access to care globally.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
1R01AG039389-01A1
Application #
8294158
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Hsiao, John
Project Start
2012-04-15
Project End
2014-03-31
Budget Start
2012-04-15
Budget End
2013-03-31
Support Year
1
Fiscal Year
2012
Total Cost
$319,367
Indirect Cost
$95,403
Name
University of North Texas
Department
Internal Medicine/Medicine
Type
Schools of Osteopathic Medicine
DUNS #
110091808
City
Fort Worth
State
TX
Country
United States
Zip Code
76107
O'Bryant, Sid E; Edwards, Melissa; Johnson, Leigh et al. (2016) A blood screening test for Alzheimer's disease. Alzheimers Dement (Amst) 3:83-90
Villarreal, Alcibiades E; O'Bryant, Sid E; Edwards, Melissa et al. (2016) Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. Neurodegener Dis Manag 6:203-13
O'Bryant, Sid E; Lista, Simone; Rissman, Robert A et al. (2016) Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. Alzheimers Dement (Amst) 3:27-34
Torrence, Nicole D; John, Samantha E; Gavett, Brandon E et al. (2016) An Empirical Comparison of Competing Factor Structures for the Repeatable Battery for the Assessment of Neuropsychological Status: A Project FRONTIER Study. Arch Clin Neuropsychol 31:88-96
Edwards, Melissa; Hall, James; Williams, Benjamin et al. (2016) Molecular markers of amnestic mild cognitive impairment among Mexican Americans. J Alzheimers Dis 49:221-8
Szerlip, Harold M; Edwards, Melissa L; Williams, Benjamin J et al. (2015) Association Between Cognitive Impairment and Chronic Kidney Disease in Mexican Americans. J Am Geriatr Soc 63:2023-8
O'Bryant, Sid E; Gupta, Veer; Henriksen, Kim et al. (2015) Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimers Dement 11:549-60
Lista, Simone; O'Bryant, Sid E; Blennow, Kaj et al. (2015) Biomarkers in Sporadic and Familial Alzheimer's Disease. J Alzheimers Dis 47:291-317
Jahn, Danielle R; Dressel, Jeffrey A; Gavett, Brandon E et al. (2015) An item response theory analysis of the Executive Interview and development of the EXIT8: A Project FRONTIER Study. J Clin Exp Neuropsychol 37:229-42
Johnson, Leigh A; Gamboa, Adriana; Vintimilla, Raul et al. (2015) Comorbid Depression and Diabetes as a Risk for Mild Cognitive Impairment and Alzheimer's Disease in Elderly Mexican Americans. J Alzheimers Dis 47:129-36

Showing the most recent 10 out of 39 publications